Table 2.
Comparison of clinical features between RA patients with and without RN
| Characteristics | With RN (n = 22) |
Without RN (n = 930) |
p value |
|---|---|---|---|
| DAS-28 | 3.02 ± 1.4 | 2.86 ± 1.33 | 0.135 |
| CDAI | 7.7 ± 8.8 | 7 ± 7.9 | 0.601 |
| SDAI | 10.4 ± 10.8 | 10 ± 10.4 | 0.779 |
| ESR, mm/h | 22.8 ± 19.3 | 24.8 ± 16.6 | 0.238 |
| Number of swollen joints | 0.51 ± 2.1 | 0.57 ± 2.2 | 0.754 |
| VAS pain | 3 ± 2.9 | 2 ± 2.7 | 0.001* |
| Number of tender joints | 6.4 ± 8.8 | 4.2 ± 7.2 | 0.001* |
| Patient's global assessment | 3.3 + 2.7 | 2.3 + 2.7 | 0.001* |
| Physician's global assessment | 1.9 + 2.1 | 1.4 + 2.0 | 0.017* |
| HAQ | 1.1 ± 0.8 | 0.9 ± 0.7 | 0.082 |
| Sicca symptoms | 8 (36.4) | 152 (16.3) | 0.025* |
| Deformities | 3 (13.6) | 74 (8.0) | 0.034* |
| Methotrexate therapy | 8 (36.4) | 341 (36.7) | 0.838 |
| Methotrexate dose, mg | 15 ± 3.8 | 15.4 ± 4 | 0.387 |
| Biologic therapy | 15 (68.2) | 478 (51.4) | 0.001* |
Values are presented as numbers (%) or means ± SD unless otherwise stated. RN, rheumatoid nodules; DAS-28, disease activity score; CDAI, clinical disease activity index; SDAI, simple disease activity index; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; HAQ, health assessment questionnaire.
*
Statistically significant.